Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TLR3 | O15455 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.38 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6559253 | 0.84 | RXRA (0.41) | MEN1KMT2ATDP1ALDH1A1MAPK1 | |
| SCHEMBL11480107 | 0.79 | HDAC3 (0.41) | MEN1KMT2ATDP1ALDH1A1MAPK1 | |
| SCHEMBL7867682 | 0.79 | TLR3 (0.44) | MEN1KMT2ATLR3ALDH1A1AKR1B1 | |
| SCHEMBL7608955 | 0.78 | MAPT (0.46) | MEN1KMT2ATLR3ALDH1A1MAPK1 | |
| SCHEMBL13090968 | 0.78 | KMT2A (0.46) | MEN1KMT2ATLR3AKR1B1MAPT | |
| SCHEMBL6560005 | 0.78 | KCNE1 (0.43) | MEN1KMT2ATDP1ALDH1A1MAPK1 | |
| SCHEMBL9141913 | 0.77 | TLR3 (0.43) | MEN1KMT2ATLR3ALDH1A1MAPK1 | |
| SCHEMBL3319440 | 0.77 | KCNE1 (0.44) | MEN1KMT2ATLR3AKR1B1 | |
| SCHEMBL3319434 | 0.77 | KCNE1 (0.44) | MEN1KMT2ATLR3AKR1B1 | |
| SCHEMBL6559550 | 0.77 | MEN1 (0.37) | MEN1KMT2ATDP1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2253333-A2 | Contrast Agents for Myocardial Perfusion Imaging | Lantheus Medical Imaging, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253333-A2 | Contrast Agents for Myocardial Perfusion Imaging | Lantheus Medical Imaging, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1740225-A4 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1740225-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105159-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | CITIZENS BANK, N.A. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | MEN1 154/4885KMT2A 4432/4885TLR3 3578/4885 |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | MEN1 154/4885KMT2A 4432/4885TLR3 3578/4885 |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | MEN1 154/4885KMT2A 4432/4885TLR3 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.